dbACP: A Comprehensive Database of Anti-Cancer Peptides

dbacp04847

General Description

Peptide name : Nigrocin-PN

Source/Organism : Black-spotted Frog, Asia

Linear/Cyclic : Not found

Chirality : Not found

Sequence Information

Sequence : GLLGKILGAGKKVLCGVSGLC

Peptide length: 21

C-terminal modification: Not found

N-terminal modification : Not found

Non-natural peptide information: None

Activity Information

Assay type : Not specified

Assay time : Not found

Activity : Not found

Cell line : Not found

Cancer type : Not found

Other activity : Anti-microbial activity; Hemolytic activity

Physicochemical Properties

Amino acid composition bar chart :

Molecular mass : 1986.4886 Dalton

Aliphatic index : 1.438

Instability index : -1.519

Hydrophobicity (GRAVY) : 1.1333

Isoelectric point : 9.3902

Charge (pH 7) : 2.7373

Aromaticity : 0

Molar extinction coefficient (cysteine, cystine): (0, 125)

Hydrophobic/hydrophilic ratio : 4.25

hydrophobic moment : -1.318

Missing amino acid : R,W,H,Q,T,P,M,E,F,D,Y,N

Most occurring amino acid : G

Most occurring amino acid frequency : 6

Least occurring amino acid : I

Least occurring amino acid frequency : 1

Structural Information

3D structure :

Secondary structure fraction (Helix, Turn, Sheet): (0.4, 0.3, 0.3)

SMILES Notation: CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)O)C(C)C)C(C)C

Secondary Structure :

Method Prediction
GOR TEEHEEEHTTTEEEEEETTEE
Chou-Fasman (CF) CCEEEECCCCCEEEEEEECCC
Neural Network (NN) CCCHHHCCCCCCEEECCCCCC
Joint/Consensus CCEEEECCCCCEEEEEECCCC

Molecular Descriptors and ADMET Properties

Molecular Descriptors: Click here to download

ADMET Properties: Click here to download

Cross Referencing databases

Pubmed Id : 35606468

Uniprot : Not available

PDB : Not available

CancerPPD : Not available

ApIAPDB : Not available

CancerPPD2 ID : Not available

Reference

1 : Lu C, et al. A novel antimicrobial peptide found in Pelophylax nigromaculatus. J Genet Eng Biotechnol. 2022; 20:76. doi: 10.1186/s43141-022-00366-9

Literature

Paper title : A novel antimicrobial peptide found in Pelophylax nigromaculatus.

Doi : https://doi.org/10.1186/s43141-022-00366-9

Abstract : BACKGROUND: Many active peptides have been found in frog skin secretions. In this paper, our research focused on Pelophylax nigromaculatus and found a broad-spectrum antimicrobial peptide Nigrocin-PN based on the molecular cloning technique. Thereafter, the "Rana box" function was briefly studied by two mutated peptides (Nigrocin-M1 and Nigrocin-M2). Furthermore, in vitro and in vivo assays were used to characterize the peptide's biofunctions, and the peptide's function in treating multidrug-resistant pathogens was also studied. RESULTS: Nigrocin-PN not only displayed potent antimicrobial abilities in vitro but also significantly ameliorated pulmonary inflammation induced by Klebsiella pneumoniae in vivo. By comparing, leucine-substituted analogue Nigrocin-M1 only displayed bactericidal abilities towards gram-positive bacteria, while the shorter analogue Nigrocin-M2 lost this function. More strikingly, Nigrocin-PN exhibited synergistic effects with commonly used antibiotics; in vitro evolution experiments revealed that coadministration between Nigrocin-PN and ampicillin could delay Staphylococcus aureus antibiotic resistance acquisition. Kinetics and morphology studies indicate that antibacterial mechanisms involved membrane destruction. Furthermore, toxicities and anticancer abilities of these peptides were also studied; compared to two analogues, Nigrocin-PN showed mild haemolytic activity and indistinctive cytotoxicity towards normal cell lines HMEC-1 and HaCaT. CONCLUSIONS: A broad-spectrum antimicrobial peptide Nigrocin-PN was discovered from the skin secretion of Pelophylax nigromaculatus. Structurally, "Rana box" played a crucial role in reducing toxicities without compromising antibacterial abilities, and Nigrocin-PN could be a desired therapeutic candidate.